Poso A - Search Results

1

Synthesis and CB1 receptor activities of dimethylheptyl derivatives of 2-arachidonoyl glycerol (2-AG) and 2-arachidonyl glyceryl ether (2-AGE).

Parkkari T, Salo OM, Huttunen KM, Savinainen JR, Laitinen JT, Poso A, Nevalainen T, Järvinen T. Parkkari T, et al. Among authors: poso a. Bioorg Med Chem. 2006 Apr 15;14(8):2850-8. doi: 10.1016/j.bmc.2005.12.007. Epub 2006 Jan 5. Bioorg Med Chem. 2006. PMID: 16403642

2

Competitive inhibition of coumarin 7-hydroxylation by pilocarpine and its interaction with mouse CYP 2A5 and human CYP 2A6.

Kinonen T, Pasanen M, Gynther J, Poso A, Järvinen T, Alhava E, Juvonen RO. Kinonen T, et al. Among authors: poso a. Br J Pharmacol. 1995 Nov;116(6):2625-30. doi: 10.1111/j.1476-5381.1995.tb17217.x. Br J Pharmacol. 1995. PMID: 8590980 Free PMC article.

3

A rhodopsin-based model for melatonin recognition at its G protein-coupled receptor.

Navajas C, Kokkola T, Poso A, Honka N, Gynther J, Laitinen JT. Navajas C, et al. Among authors: poso a. Eur J Pharmacol. 1996 May 23;304(1-3):173-83. doi: 10.1016/0014-2999(96)00114-8. Eur J Pharmacol. 1996. PMID: 8813600

4

Molecular determinants of steroid inhibition for the mouse constitutive androstane receptor.

Jyrkkärinne J, Mäkinen J, Gynther J, Savolainen H, Poso A, Honkakoski P. Jyrkkärinne J, et al. Among authors: poso a. J Med Chem. 2003 Oct 23;46(22):4687-95. doi: 10.1021/jm030861t. J Med Chem. 2003. PMID: 14561088

5

Development of a 3D model for the human cannabinoid CB1 receptor.

Salo OM, Lahtela-Kakkonen M, Gynther J, Järvinen T, Poso A. Salo OM, et al. Among authors: poso a. J Med Chem. 2004 Jun 3;47(12):3048-57. doi: 10.1021/jm031052c. J Med Chem. 2004. PMID: 15163186

6

An in silico approach to discovering novel inhibitors of human sirtuin type 2.

Tervo AJ, Kyrylenko S, Niskanen P, Salminen A, Leppänen J, Nyrönen TH, Järvinen T, Poso A. Tervo AJ, et al. Among authors: poso a. J Med Chem. 2004 Dec 2;47(25):6292-8. doi: 10.1021/jm049933m. J Med Chem. 2004. PMID: 15566299

7

Identification of WIN55212-3 as a competitive neutral antagonist of the human cannabinoid CB2 receptor.

Savinainen JR, Kokkola T, Salo OM, Poso A, Järvinen T, Laitinen JT. Savinainen JR, et al. Among authors: poso a. Br J Pharmacol. 2005 Jul;145(5):636-45. doi: 10.1038/sj.bjp.0706230. Br J Pharmacol. 2005. PMID: 15852035 Free PMC article.

8

Targeting the cannabinoid CB2 receptor: mutations, modeling and development of CB2 selective ligands.

Raitio KH, Salo OM, Nevalainen T, Poso A, Järvinen T. Raitio KH, et al. Among authors: poso a. Curr Med Chem. 2005;12(10):1217-37. doi: 10.2174/0929867053764617. Curr Med Chem. 2005. PMID: 15892633 Review.

9

Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors.

Korhonen LE, Rahnasto M, Mähönen NJ, Wittekindt C, Poso A, Juvonen RO, Raunio H. Korhonen LE, et al. Among authors: poso a. J Med Chem. 2005 Jun 2;48(11):3808-15. doi: 10.1021/jm0489713. J Med Chem. 2005. PMID: 15916432

10

BRUTUS: optimization of a grid-based similarity function for rigid-body molecular superposition. 1. Alignment and virtual screening applications.

Tervo AJ, Rönkkö T, Nyrönen TH, Poso A. Tervo AJ, et al. Among authors: poso a. J Med Chem. 2005 Jun 16;48(12):4076-86. doi: 10.1021/jm049123a. J Med Chem. 2005. PMID: 15943481

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

303 results

Search Page

Filters